title: Coexistence of normal and clonal haemopoiesis in aplastic anaemia patients treated with immunosuppressive therapy.
abstract: Cytogenetic abnormalities and paroxysmal nocturnal haemoglobinuria (PNH) phenotype are frequent findings in aplastic anaemia patients treated with immunosuppressive therapy (IST). In this study we investigated whether the appearance of clonal haemopoiesis influences patient outcome and survival. 97 patients entered this study and were followed from the onset of the disease for a median follow-up (FU) of 53 months. 93% are alive, 56% achieved complete remission, 30% partial remission, both transfusion independent, and 14% did not respond. Three groups were identified: (A) patients without evidence of emerging clones (71/97); (B) patients who acquired chromosomal abnormalities (13/97); (C) patients who showed low expression of glycosyl phosphatidylinositol anchored proteins (GPI-AP) (PNH phenotype) at presentation or later (16/97). Three patients showed both PIG-AP deficiency and chromosomal abnormalities. The actuarial survival of patients without clonal haemopoiesis (n = 71) at 6 years was 95%, for patients with chromosomal abnormalities (n = 13), 88%, and for patients with PIG-AP deficiency (n = 16), 89%. There was no difference in the probability of becoming transfusion independent in the three groups (93%, 92% and 88% respectively). This study confirmed that a proportion of severe aplastic anaemia (SAA) patients exhibit clonal markers during the time after IST, often coexisting with cytogenetically or phenotypically normal haemopoiesis. There was no significant clinical impact of these abnormalities on transfusion independence and survival at the median follow-up of 4 years.
authors.affiliation: Dipartimento di Ematologia, Ospedale S. Martino, Genova, Italy. giovannapiaggio@smartino.ge.it
authors.forename: G
authors.initials: G
authors.lastname: Piaggio
authors.forename: M
authors.initials: M
authors.lastname: Podestà
authors.forename: A
authors.initials: A
authors.lastname: Pitto
authors.forename: M
authors.initials: M
authors.lastname: Sessarego
authors.forename: O
authors.initials: O
authors.lastname: Figari
authors.forename: G
authors.initials: G
authors.lastname: Fugazza
authors.forename: F
authors.initials: F
authors.lastname: Benvenuto
authors.forename: B
authors.initials: B
authors.lastname: Bruno
authors.forename: M T
authors.initials: MT
authors.lastname: Van Lint
authors.forename: M
authors.initials: M
authors.lastname: Truini
authors.forename: F
authors.initials: F
authors.lastname: Frassoni
authors.forename: A
authors.initials: A
authors.lastname: Bacigalupo
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000741:Anemia, Aplastic / Q000473:pathology* / Q000628:therapy; D002648:Child; D005260:Female; D005434:Flow Cytometry; D006410:Hematopoiesis / Q000502:physiology*; D006412:Hematopoietic Stem Cells / Q000473:pathology; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D008297:Male; D008875:Middle Aged; D016019:Survival Analysis; D016896:Treatment Outcome